Chemist + Druggist is part of Pharma Intelligence UK Limited

This is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By


Stop services or raise loans? How contractors are coping with the cuts

What did the C+D Salary Survey 2017 reveal about the financial impact of funding cuts on England's community pharmacy owners?

The C+D Salary Survey 2017 – which ran throughout October – revealed that 79% of contractors in England experienced a drop in their income in the previous 12 months, which spanned the Department of Health's imposition of a 12% cut to the country's community pharmacy budget.

But how are pharmacy owners in England trying to cope with the biggest financial challenge in recent memory? Below are a selection of key findings from C+D's survey:

C+D Salary Survey 2017
What impact have the funding cuts had on pharmacy owners?


Click here to find out in contractors' own words what it was like to be a pharmacy owner in England in the first year of the funding cuts.

The C+D Salary Survey 2017 – which ran throughout October – was completed by a total of 1,754 pharmacists and pharmacy staff. C+D's ongoing coverage from the survey can be found here.


Lead Pharmacist
£30 per hour

Apply Now
Latest News & Analysis
See All



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts